90 related articles for article (PubMed ID: 6140693)
1. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Methodological considerations, sample population, and research variables.
Rein W; Schied HW; Breyer-Pfaff U; Straube E
Pharmacopsychiatria; 1983 Sep; 16(5):147-51. PubMed ID: 6140693
[TBL] [Abstract][Full Text] [Related]
2. Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results.
Schied HW; Rein W; Straube E; Jung H; Breyer-Pfaff U
Pharmacopsychiatria; 1983 Sep; 16(5):152-9. PubMed ID: 6140694
[TBL] [Abstract][Full Text] [Related]
3. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data.
Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E
Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695
[TBL] [Abstract][Full Text] [Related]
4. Autonomic nervous system differences as predictors of short-term outcome in schizophrenics.
Straube ER; Schied HW; Rein W; Breyer-Pfaff U
Pharmacopsychiatry; 1987 May; 20(3):105-10. PubMed ID: 2885864
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
Dieterle DM; Müller-Spahn F; Ackenheil M
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334
[TBL] [Abstract][Full Text] [Related]
6. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.
Gaebel W; Pietzcker A; Ulrich G; Schley J; Müller-Oerlinghausen B
Pharmacopsychiatry; 1988 Nov; 21(6):384-6. PubMed ID: 2907645
[No Abstract] [Full Text] [Related]
7. [Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness].
Wetzel H; von Bardeleben U; Holsboer F; Benkert O
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():23-9. PubMed ID: 1683336
[TBL] [Abstract][Full Text] [Related]
8. [A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study].
Schmidt LG; Siemetzki H
Nervenarzt; 1988 Dec; 59(12):721-6. PubMed ID: 2905770
[No Abstract] [Full Text] [Related]
9. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
[No Abstract] [Full Text] [Related]
12. Orthostatic challenge during neuroleptic test dose: a possible predictor of short-term outcome.
Volz HP; Mackert A; Diefenbacher A; Friedrich A; Gaebel W; Müller H; Stock G; Möller HJ
Neuropsychobiology; 1994; 30(2-3):94-100. PubMed ID: 7800170
[TBL] [Abstract][Full Text] [Related]
13. [Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and a double-blind controlled trial].
Müller-Spahn F; Dieterle D; Ackenheil M
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():30-5. PubMed ID: 1683337
[TBL] [Abstract][Full Text] [Related]
14. [Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients].
Möller HJ; Scharl W; von Zerssen D
Fortschr Neurol Psychiatr; 1985 Oct; 53(10):370-83. PubMed ID: 2866152
[TBL] [Abstract][Full Text] [Related]
15. Suspension of neuroleptic therapy in acute schizophrenia.
Kuhs H; Eikelmann B
Pharmacopsychiatry; 1988 Jul; 21(4):197-202. PubMed ID: 2905064
[TBL] [Abstract][Full Text] [Related]
16. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients.
Nedopil N; Pflieger R; Rüther E
Pharmacopsychiatria; 1983 Nov; 16(6):201-5. PubMed ID: 6141576
[TBL] [Abstract][Full Text] [Related]
17. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
[TBL] [Abstract][Full Text] [Related]
19. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
20. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
